Image of spreadsheets on glass table during discussion of strategy

Axovant Sciences Ltd. (NYSE:AXON) shares traded -6.06% down during most recent session to reach at the closing price of $2.48. The stock exchanged hands 3.23 Million shares versus average trading capacity of 6.13 Million shares, yielding a market cap of $279.87 Million. Wall Street analysts covering the stock are projecting that the stock will reach $6 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Axovant Sciences Ltd. (NYSE:AXON) high price target of $11 and with a conservative view have low price target of $4.

Cowen & Co. “Downgrades” Axovant Sciences Ltd. (NYSE:AXON) in a research note issued to investors on 1/12/18 to Market Perform.

Additionally on 1/10/18 Chardan Capital “Upgrades” Axovant Sciences Ltd. (NYSE:AXON) to Neutral setting price target at $2 and on 12/21/17 Jefferies “Downgrades” the stock to Hold. Furthermore on 9/26/17 Oppenheimer “Downgrades” the stock to Perform.

On the other hand the company has Relative Strength Index (RSI 14) of 47.97 along with Average True Range (ATR 14) of 0.49, Consequently Axovant Sciences Ltd. (NYSE:AXON)’s weekly and monthly volatility is 15.06%, 13.93% respectively. The company’s beta value is at 0.

In terms of Buy, Sell or Hold recommendations, Axovant Sciences Ltd. (NYSE:AXON) has analysts’ mean recommendation of 2.7. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Axovant Sciences Ltd. (NYSE:AXON)’s minimum EPS for the current quarter is at $-0.23 and can go high up to $-0.13. The consensus mean EPS for the current quarter is at $-0.18 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.65 earnings per share for the same quarter during last year.

Previously Axovant Sciences Ltd. (NYSE:AXON) reported $-0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.36 by $0.13. The company posted an earnings surprise of 36.1%.

Currently Axovant Sciences Ltd. (NYSE:AXON)’s shares owned by insiders are 82.9%, whereas shares owned by institutional owners are 15.6%. However the six-month change in the insider ownership was recorded 122.16%, as well as three-month change in the institutional ownership was recorded 0.03%.

Axovant Sciences Ltd. (NYSE:AXON)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $0.66 while its price to book ratio for the same period is 3.76, as for as the company’s cash per share for the most recent quarter is $1.37, however its price to cash per share ratio for the same period is 1.81. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.